<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Moderna Inc — News on 6ix</title>
<link>https://6ix.com/company/moderna-inc</link>
<description>Latest news and press releases for Moderna Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 21 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/moderna-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68359d2978dffbe2df107784.webp</url>
<title>Moderna Inc</title>
<link>https://6ix.com/company/moderna-inc</link>
</image>
<item>
<title>Moderna Announces Initiation of Phase 3 Study of Investigational mRNA Pandemic Influenza Vaccine Candidate</title>
<link>https://6ix.com/company/moderna-inc/news/moderna-announces-initiation-of-phase-3-study-of-investigational-mrna-pandemic-influenza-vaccine-candidate-2</link>
<guid isPermaLink="true">https://6ix.com/company/moderna-inc/news/moderna-announces-initiation-of-phase-3-study-of-investigational-mrna-pandemic-influenza-vaccine-candidate-2</guid>
<pubDate>Tue, 21 Apr 2026 04:00:00 GMT</pubDate>
<description>Phase 3 study is supported by the Coalition for Epidemic Preparedness Innovations to help strengthen global preparedness against a significant pandemic threat</description>
</item>
<item>
<title>Moderna to Report First Quarter 2026 Financial Results on Friday, May 1, 2026</title>
<link>https://6ix.com/company/moderna-inc/news/moderna-to-report-first-quarter-2026-financial-results-on-friday-may-1-2026</link>
<guid isPermaLink="true">https://6ix.com/company/moderna-inc/news/moderna-to-report-first-quarter-2026-financial-results-on-friday-may-1-2026</guid>
<pubDate>Wed, 15 Apr 2026 11:00:00 GMT</pubDate>
<description>CAMBRIDGE, MA / ACCESS Newswire / April 15, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, May 1,2026 to report its first quarter 2026 financial results, and provide ...</description>
</item>
<item>
<title>Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026</title>
<link>https://6ix.com/company/moderna-inc/news/moderna-to-present-revaccination-data-for-its-investigational-seasonal-influenza-vaccine-and-for-mresvia-at-escmid-2026</link>
<guid isPermaLink="true">https://6ix.com/company/moderna-inc/news/moderna-to-present-revaccination-data-for-its-investigational-seasonal-influenza-vaccine-and-for-mresvia-at-escmid-2026</guid>
<pubDate>Mon, 06 Apr 2026 22:01:00 GMT</pubDate>
<description>CAMBRIDGE, MA / ACCESS Newswire / April 6, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present late-breaking oral presentations on revaccination data for both mRNA-1010, its investigational seasonal influenza vaccine, ...</description>
</item>
<item>
<title>Moderna Resolves Global Patent Litigation with Arbutus/Genevant</title>
<link>https://6ix.com/company/moderna-inc/news/moderna-resolves-global-patent-litigation-with-arbutusgenevant</link>
<guid isPermaLink="true">https://6ix.com/company/moderna-inc/news/moderna-resolves-global-patent-litigation-with-arbutusgenevant</guid>
<pubDate>Tue, 03 Mar 2026 21:15:00 GMT</pubDate>
<description>Moderna to pay $950 million with no future royalties to resolve all global litigation; corresponding charge expected in Q1 2026 District Court's Section 1498 decision to be appealed to the Federal Circuit Court of Appeals with potential additional ...</description>
</item>
<item>
<title>European Medicines Agency's Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Marketing Authorization of mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19</title>
<link>https://6ix.com/company/moderna-inc/news/european-medicines-agencys-committee-for-medicinal-products-for-human-use-adopts-positive-opinion-recommending-marketing-authorization-of-mcombriax-modernas-mrna-combination-vaccine-against-influenza-and-covid-19</link>
<guid isPermaLink="true">https://6ix.com/company/moderna-inc/news/european-medicines-agencys-committee-for-medicinal-products-for-human-use-adopts-positive-opinion-recommending-marketing-authorization-of-mcombriax-modernas-mrna-combination-vaccine-against-influenza-and-covid-19</guid>
<pubDate>Fri, 27 Feb 2026 05:00:00 GMT</pubDate>
<description>mCOMBRIAX is the world's first flu plus COVID combination vaccine to receive a positive CHMP opinion recommending marketing authorization and represents</description>
</item>
<item>
<title>Moderna to Present at Upcoming Conferences in March 2026</title>
<link>https://6ix.com/company/moderna-inc/news/moderna-to-present-at-upcoming-conferences-in-march-2026</link>
<guid isPermaLink="true">https://6ix.com/company/moderna-inc/news/moderna-to-present-at-upcoming-conferences-in-march-2026</guid>
<pubDate>Thu, 19 Feb 2026 05:00:00 GMT</pubDate>
<description>CAMBRIDGE, MASSACHUSETTS / ACCESS Newswire / February 19, 2026 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming</description>
</item>
<item>
<title>Moderna Announces the U.S. Food and Drug Administration will Initiate the Review of Its Investigational Seasonal Influenza Vaccine Submission</title>
<link>https://6ix.com/company/moderna-inc/news/moderna-announces-the-us-food-and-drug-administration-will-initiate-the-review-of-its-investigational-seasonal-influenza-vaccine-submission</link>
<guid isPermaLink="true">https://6ix.com/company/moderna-inc/news/moderna-announces-the-us-food-and-drug-administration-will-initiate-the-review-of-its-investigational-seasonal-influenza-vaccine-submission</guid>
<pubDate>Wed, 18 Feb 2026 05:00:00 GMT</pubDate>
<description>Following a Type A meeting, the FDA's Center for Biologics Evaluation and Research has notified Moderna that its biologics license application for mRNA-1010</description>
</item>
<item>
<title>Moderna Receives European Commission Marketing Authorization for COVID-19 Vaccine mNEXSPIKE</title>
<link>https://6ix.com/company/moderna-inc/news/moderna-receives-european-commission-marketing-authorization-for-covid-19-vaccine-mnexspike</link>
<guid isPermaLink="true">https://6ix.com/company/moderna-inc/news/moderna-receives-european-commission-marketing-authorization-for-covid-19-vaccine-mnexspike</guid>
<pubDate>Tue, 17 Feb 2026 05:00:00 GMT</pubDate>
<description>mNEXSPIKE is the third Moderna vaccine authorized in the European Union, strengthening the Company's respiratory vaccine portfolio in Europe CAMBRIDGE, MA /</description>
</item>
<item>
<title>Moderna Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Updates</title>
<link>https://6ix.com/company/moderna-inc/news/moderna-reports-fourth-quarter-and-fiscal-year-2025-financial-results-and-provides-business-updates</link>
<guid isPermaLink="true">https://6ix.com/company/moderna-inc/news/moderna-reports-fourth-quarter-and-fiscal-year-2025-financial-results-and-provides-business-updates</guid>
<pubDate>Fri, 13 Feb 2026 05:00:00 GMT</pubDate>
<description>Reports fourth quarter revenue of $0.7 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.11)Reports full-year revenue of $1.9 billion, GAAP net</description>
</item>
<item>
<title>Moderna Receives Refusal-to-File Letter from the U.S. Food and Drug Administration for Its Investigational Seasonal Influenza Vaccine, mRNA-1010</title>
<link>https://6ix.com/company/moderna-inc/news/moderna-receives-refusal-to-file-letter-from-the-us-food-and-drug-administration-for-its-investigational-seasonal-influenza-vaccine-mrna-1010</link>
<guid isPermaLink="true">https://6ix.com/company/moderna-inc/news/moderna-receives-refusal-to-file-letter-from-the-us-food-and-drug-administration-for-its-investigational-seasonal-influenza-vaccine-mrna-1010</guid>
<pubDate>Tue, 10 Feb 2026 05:00:00 GMT</pubDate>
<description>Refusal to review the submission is inconsistent with feedback at pre-Phase 3 and pre-submission consultations; Moderna has requested a Type A meeting to</description>
</item>
<item>
<title>Moderna to Enter into Long-Term Strategic Agreement with the Government of Mexico</title>
<link>https://6ix.com/company/moderna-inc/news/moderna-to-enter-into-long-term-strategic-agreement-with-the-government-of-mexico</link>
<guid isPermaLink="true">https://6ix.com/company/moderna-inc/news/moderna-to-enter-into-long-term-strategic-agreement-with-the-government-of-mexico</guid>
<pubDate>Tue, 10 Feb 2026 05:00:00 GMT</pubDate>
<description>Signed Memorandum of Understanding supports "Plan Mexico," Mexico's strategic initiative to build a local mRNA ecosystem and strengthen health</description>
</item>
<item>
<title>How Moderna Uses Decision Intelligence to Enable an Autonomous Cold Chain, Upcoming Webinar Hosted by Xtalks</title>
<link>https://6ix.com/company/moderna-inc/news/moderna-uses-decision-intelligence-enable-133000814</link>
<guid isPermaLink="true">https://6ix.com/company/moderna-inc/news/moderna-uses-decision-intelligence-enable-133000814</guid>
<pubDate>Tue, 03 Feb 2026 13:30:00 GMT</pubDate>
<description>Cold chain logistics within pharmaceutical supply chains are undergoing a fundamental transformation as organizations confront rising product complexity, expanding global networks and mounting pressure to reduce waste, cost and manual intervention. Join this webinar to learn about Moderna's evolving blueprint for enabling an autonomous cold chain, highlighting how blind spot elimination, data consolidation and decision intelligence can unlock meaningful operational change.</description>
</item>
<item>
<title>Dr. David Berman to Join Moderna as Chief Development Officer</title>
<link>https://6ix.com/company/moderna-inc/news/dr-david-berman-join-moderna-123000891</link>
<guid isPermaLink="true">https://6ix.com/company/moderna-inc/news/dr-david-berman-join-moderna-123000891</guid>
<pubDate>Fri, 30 Jan 2026 12:30:00 GMT</pubDate>
<description>CAMBRIDGE, MASSACHUSETTS / ACCESS Newswire / January 30, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that David Berman, M.D., Ph.D. has been appointed as the Company's Chief Development Officer, beginning March 2, 2026. He will serve on Moderna's ...</description>
</item>
<item>
<title>Moderna Announces Strategic Collaboration with Recordati to Globally Commercialize Investigational Propionic Acidemia Therapeutic (mRNA-3927)</title>
<link>https://6ix.com/company/moderna-inc/news/moderna-announces-strategic-collaboration-recordati-globally-commercialize</link>
<guid isPermaLink="true">https://6ix.com/company/moderna-inc/news/moderna-announces-strategic-collaboration-recordati-globally-commercialize</guid>
<pubDate>Thu, 29 Jan 2026 05:00:00 GMT</pubDate>
<description>Moderna will continue to lead clinical development and manufacturing for mRNA-3927Moderna to receive up to $160 million in upfront and near-term development</description>
</item>
<item>
<title>Moderna to Report Fourth Quarter 2025 Financial Results on Friday, February 13, 2026</title>
<link>https://6ix.com/company/moderna-inc/news/moderna-report-fourth-quarter-2025-financial-results-friday-february-13-2026-2026-01</link>
<guid isPermaLink="true">https://6ix.com/company/moderna-inc/news/moderna-report-fourth-quarter-2025-financial-results-friday-february-13-2026-2026-01</guid>
<pubDate>Mon, 26 Jan 2026 05:00:00 GMT</pubDate>
<description>CAMBRIDGE, MA / ACCESS Newswire / January 26, 2026 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00</description>
</item>
<item>
<title>Moderna & Merck Announce 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in Patients With High-Risk Stage III/IV Melanoma Follow...</title>
<link>https://6ix.com/company/moderna-inc/news/moderna-merck-announce-5-year-data-intismeran-autogene-combination-keytrudar</link>
<guid isPermaLink="true">https://6ix.com/company/moderna-inc/news/moderna-merck-announce-5-year-data-intismeran-autogene-combination-keytrudar</guid>
<pubDate>Tue, 20 Jan 2026 05:00:00 GMT</pubDate>
<description>Moderna & Merck Announce 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in the Primary</description>
</item>
<item>
<title>Moderna Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/moderna-inc/news/moderna-provides-business-and-pipeline-updates-44th-annual-jp-morgan-healthcare</link>
<guid isPermaLink="true">https://6ix.com/company/moderna-inc/news/moderna-provides-business-and-pipeline-updates-44th-annual-jp-morgan-healthcare</guid>
<pubDate>Mon, 12 Jan 2026 05:00:00 GMT</pubDate>
<description>Expects 2025 revenue of approximately $1.9 billion (unaudited), $100 million above midpoint communicated on 3Q25 Earnings CallImproves 2025 expected GAAP</description>
</item>
<item>
<title>Moderna Announces Global Regulatory Submissions for Its Investigational Seasonal Influenza Vaccine</title>
<link>https://6ix.com/company/moderna-inc/news/moderna-announces-global-regulatory-submissions-its-investigational-seasonal</link>
<guid isPermaLink="true">https://6ix.com/company/moderna-inc/news/moderna-announces-global-regulatory-submissions-its-investigational-seasonal</guid>
<pubDate>Mon, 05 Jan 2026 05:00:00 GMT</pubDate>
<description>Moderna has filed for marketing authorization in the U.S., EU, Canada and Australia for mRNA-1010 CAMBRIDGE, MA / ACCESS Newswire / January 5, 2026 / Moderna,</description>
</item>
<item>
<title>CEPI to Fund Pivotal Phase 3 Trial for Moderna's mRNA Pandemic Influenza Vaccine Candidate</title>
<link>https://6ix.com/company/moderna-inc/news/cepi-to-fund-pivotal-phase-3-trial-for-modernas-mrna-pandemic-influenza-vaccine-candidate</link>
<guid isPermaLink="true">https://6ix.com/company/moderna-inc/news/cepi-to-fund-pivotal-phase-3-trial-for-modernas-mrna-pandemic-influenza-vaccine-candidate</guid>
<pubDate>Thu, 18 Dec 2025 12:00:00 GMT</pubDate>
<description>Up to $54.3 million CEPI investment aims to help advance Moderna's H5 pandemic influenza vaccine candidate to licensure Partnership strengthens global preparedness against a significant pandemic threat If licensed and in the event of an influenza ...</description>
</item>
<item>
<title>Moderna to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/moderna-inc/news/moderna-present-44th-annual-jp-morgan-healthcare-conference-2025-12-17</link>
<guid isPermaLink="true">https://6ix.com/company/moderna-inc/news/moderna-present-44th-annual-jp-morgan-healthcare-conference-2025-12-17</guid>
<pubDate>Wed, 17 Dec 2025 05:00:00 GMT</pubDate>
<description>CAMBRIDGE, MA / ACCESS Newswire / December 17, 2025 / Moderna, Inc. (Nasdaq:MRNA) today announced it will present at the 44th annual J.P. Morgan Healthcare</description>
</item>
</channel>
</rss>